Search results
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with...
Benzinga· 5 days agoNew data from the ELATIVEĀ® Phase III trial show 70% of patients treated with elafibranor achieved composite endpoint of slowing disease progression measured by biochemical response after 78-weeksData from the itch